Close Menu

This story has been updated with additional details on the FDA approved companion test for Alunbrig and about how patients were genetically tested in the ALTA 1L study. 

NEW YORK – The US Food and Drug Administration on Friday approved Takeda Pharmaceutical's brigatinib (Alunbrig) as a treatment for ALK-positive, metastatic non-small cell lung cancer.

The agency simultaneoulsy approved Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit to identify patients with ALK rearrangements who are likely to benefit from brigatinib.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.